OverviewSuggest Edit

Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

TypePublic
Founded2008
HQPhiladelphia, PA, US
Websiteadaptimmune.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2019)400(-6%)
Job Openings64
Revenue (FY, 2020)$4 M(+253%)
Share Price (Apr 2021)$4.7(-5%)
Cybersecurity ratingBMore

Key People/Management at Adaptimmune

David M. Mott

David M. Mott

Chairman
Gavin Wood

Gavin Wood

Chief Financial Officer
Lawrence M. Alleva

Lawrence M. Alleva

Non-Executive Director
Mark Dudley

Mark Dudley

Senior Vice President, Early Stage Development
Helen Tayton-Martin

Helen Tayton-Martin

Chief Business Officer
Ali Behbahani

Ali Behbahani

Non-Executive Director
Show more

Adaptimmune Office Locations

Adaptimmune has offices in Philadelphia, Milton and Stevenage
Philadelphia, PA, US (HQ)
351 Rouse Blvd
Milton, GB
101 Park Dr
Milton, GB
60 Jubilee Ave
Stevenage, GB
Gunnels Wood Rd
Show all (4)

Adaptimmune Financials and Metrics

Adaptimmune Revenue

Adaptimmune's revenue was reported to be $3.96 m in FY, 2020
USD

Revenue (FY, 2020)

4.0m

Net income (FY, 2020)

(130.1m)

EBIT (FY, 2020)

(133.4m)

Market capitalization (19-Apr-2021)

727.7m

Closing stock price (19-Apr-2021)

4.7

Cash (31-Dec-2020)

56.9m

EV

694.5m
Adaptimmune's current market capitalization is $727.7 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

14.2m37.8m59.5m1.1m4.0m

EBIT

(72.8m)(80.7m)(82.4m)(139.8m)(133.4m)

EBIT margin, %

(513%)(213%)(138%)(12457%)(3371%)

Interest expense

1.1m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

2.9m328.0k2.4m2.9m3.5m27.2m8.2m9.0m40.8m157.0k237.0k761.0k502.0k1.2m

General and administrative expense

11.8m10.1m9.3m10.3m13.0m

R&D expense

22.0m25.5m21.3m20.5m24.1m

Operating expense total

33.8m35.7m30.5m30.8m37.1m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

158.8m84.0m68.4m50.4m56.9m

Accounts Receivable

149.5k206.0k192.0k139.0k

Prepaid Expenses

21.7m25.8m30.9m29.8m

Inventories

1.4m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(23.0m)(70.1m)(95.5m)(137.2m)(130.1m)

Depreciation and Amortization

5.4m7.8m8.0m7.6m

Accounts Payable

3.9m

Cash From Operating Activities

(48.2m)(54.3m)(104.4m)(112.5m)(53.6m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(15.6m)(37.7m)(56.2m)(21.8m)(42.0m)(42.9m)(21.1m)(64.6m)(59.3m)(27.4m)(68.5m)(107.8m)(28.2m)(58.0m)(93.5m)

Depreciation and Amortization

707.0k1.5m2.3m1.0m2.2m3.7m1.9m3.8m5.7m2.0m4.0m5.9m1.7m3.6m5.2m

Accounts Payable

(2.7m)3.6m(117.0k)

Cash From Operating Activities

(18.7m)(35.2m)(50.5m)(28.4m)(46.4m)(33.0m)(47.3m)(82.6m)(72.7m)(36.2m)(70.4m)(100.0m)16.9m(8.1m)(24.4m)
USDQ1, 2016

Financial Leverage

1.2 x
Show all financial metrics

Adaptimmune Operating Metrics

FY, 2016

Patent Applications

69

Patents Issued

173
Show all operating metrics

Adaptimmune Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Adaptimmune Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Adaptimmune Online and Social Media Presence

Embed Graph

Adaptimmune News and Updates

Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update

- Outlined strategy to build integrated cell therapy company and the Company’s “2-2-5-2” five-year core value drivers -

Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and year ended December 31, 2020, before the US ma…

Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day

- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -

Adaptimmune to Host Virtual Investor Day on Friday, November 20th

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor Day on November 20, 2020 at 8AM EST/ 1PM GMT. A link to register is available HERE and further details …

Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020

PHILADELPHIA and OXFORDSHIRE, U.K., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q3 2020, before the U.S. markets open on Thursday, November 5, 2020. Following…

Adaptimmune Reports Q2 Financial Results and Business Update

- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 -
Show more

Adaptimmune Blogs

Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC

- Data support continued development of ADP-A2M4CD8 - - On track to start Phase 2 trial in gastroesophageal cancers in the first half of 2021 - PHILADELPHIA, Pa. and OXFORDSHIRE, UK., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat…

Adaptimmune Reports Q3 Financial Results and Business Update

- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients - - Safety and response data from dose escalation cohorts of the SURPASS trial to be presented at SITC - - Durability of response data from patients with …

Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the early release of the abstract entitled “Initial safety, efficacy, and product attributes from the SU…

Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 23, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative to the Company for ADP-A2M4 for the tr…

Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. markets open on Thursday, August 6, 2020. F…

SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ Cancer

- New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy - - Durability and efficacy data presented at ASCO support potential for SPEARHEAD-1 as a registrational trial for sarcoma - commercial launch planned in the US …
Show more

Adaptimmune Frequently Asked Questions

  • When was Adaptimmune founded?

    Adaptimmune was founded in 2008.

  • Who are Adaptimmune key executives?

    Adaptimmune's key executives are David M. Mott, Gavin Wood and Lawrence M. Alleva.

  • How many employees does Adaptimmune have?

    Adaptimmune has 400 employees.

  • What is Adaptimmune revenue?

    Latest Adaptimmune annual revenue is $4 m.

  • What is Adaptimmune revenue per employee?

    Latest Adaptimmune revenue per employee is $9.9 k.

  • Who are Adaptimmune competitors?

    Competitors of Adaptimmune include Bellicum Pharmaceuticals, Novavax and Wren Therapeutics.

  • Where is Adaptimmune headquarters?

    Adaptimmune headquarters is located at 351 Rouse Blvd, Philadelphia.

  • Where are Adaptimmune offices?

    Adaptimmune has offices in Philadelphia, Milton and Stevenage.

  • How many offices does Adaptimmune have?

    Adaptimmune has 4 offices.